Author Page for Satoru Iwasa

Docetaxel Plus Cisplatin and S-1 versus Cisplatin and S-1 in Patients with Advanced Gastric Cancer (JCOG1013): An Open-Label, Randomised, Phase 3 Trial

Number of pages: 100 Posted: 04 Feb 2019

National Cancer Center Hospital - Gastrointestinal Medical Oncology Division, St. Marianna University - Department of Medical Oncology, National Cancer Center Hospital, National Cancer Center Hospital - Gastrointestinal Medical Oncology Division, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, National Cancer Center Hospital East, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Shizuoka Cancer Centre, National Cancer Center Hospital, Nagoya University - Graduate School of Medicine, National Cancer Center Hospital - Department of Gastric Surgery, affiliation not provided to SSRN, Shizuoka Cancer Centre, Independent and Independent

Downloads 114 (621,896)

Abstract:

2.

Olanzapine 5mg in Combination with Standard Antiemetic Therapy for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Cisplatin-Based Chemotherapy (J-FORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial

Number of pages: 107 Posted: 07 Jul 2019

Hironobu Hashimoto, Masakazu Abe, Osamu Tokuyama, Hideaki Mizutani, Yosuke Uchitomi, Takuhiro Yamaguchi, Yukari Hoshina, Yasuhiko Sakata, Takako Yanai, Kazuhisa Nakashima, Masahiko Nakao, Daisuke Takei, Sadamoto Zenda, Koki Mizukami, Satoru Iwasa, Michiru i Sakura, Noboru Yamamoto and Yuichiro Ohe

National Cancer Center Hospital, Shizuoka Cancer Center - Department of Gynecologic Oncology, Osaka City General Hospital, Saitama Cancer Center, National Cancer Center Hospital, Tohoku University - Graduate School of Medicine, National Cancer Center Hospital, Hiroshima City Hiroshima Citizens Hospital, National Cancer Center Hospital, Shizuoka Cancer Center, Osaka City General Hospital, Saitama Cancer Center, National Cancer Center Hospital, Hiroshima City Hiroshima Citizens Hospital, National Cancer Center Hospital - Gastrointestinal Medical Oncology Division, Shizuoka Cancer Center, National Cancer Center Hospital - Department of Experimental Therapeutics and National Cancer Center Hospital

Downloads 92 (730,864)

Abstract:

3.

Predictive Correlates of Response to Nivolumab in Japanese Patients with Esophageal Cancer

Number of pages: 163 Posted: 27 Sep 2018

Ken Kato, Yuichiro Doki, Takashi Ura, Yasuo Hamamoto, Takashi Kojima, Takahiro Tsushima, Shuichi Hironaka, Shuichi Hironaka, Hiroki Hara, Toshihiro Kudo, Satoru Iwasa, Kei Muro, Hirofumi Yasui, Keiko Minashi, Kensei Yamaguchi, Atsushi Ohtsu and Yuko Kitagawa

National Cancer Center Hospital - Gastrointestinal Medical Oncology Division, The University of Osaka - Department of Gastroenterological Surgery, Aichi Cancer Center, Keio University, National Cancer Center Hospital East, Shizuoka Cancer Centre, Oita UniversityChiba Cancer Center, Saitama Cancer Center, The University of Osaka, National Cancer Center Hospital - Gastrointestinal Medical Oncology Division, Aichi Cancer Center, Shizuoka Cancer Centre, Chiba Cancer Center, Saitama Cancer Center, National Cancer Center Hospital East and Keio University

Downloads 56 (1,000,027)

Satoru Iwasa

National Cancer Center Hospital - Gastrointestinal Medical Oncology Division

3

262

0

Scholarly Papers (3)

Docetaxel Plus Cisplatin and S-1 versus Cisplatin and S-1 in Patients with Advanced Gastric Cancer (JCOG1013): An Open-Label, Randomised, Phase 3 Trial

Abstract:

Olanzapine 5mg in Combination with Standard Antiemetic Therapy for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Cisplatin-Based Chemotherapy (J-FORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial

Abstract:

Predictive Correlates of Response to Nivolumab in Japanese Patients with Esophageal Cancer

Abstract: